-
Sector Analysis
NewContrast Agents Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033
Contrast Agents Market Report Overview The contrast agents market size was $3.41 billion in 2023. Factors such as the rising prevalence of chronic diseases and the increased demand for cost-effective and quality healthcare will drive the market growth at a CAGR of more than 2% from 2023 to 2033. Contrast agents are used in radiology to get clearer visualizations of various medical conditions and pathologies. These agents are used with computed tomography (CT), magnetic resonance imaging (MRI), and ultrasounds, among...
-
Sector Analysis
NewContrast Media Injectors Market Size by Segments, Share, Regulatory, Reimbursement, Installed Base and Forecast to 2033
The Contrast Media Injectors Market Report Overview The contrast media injectors market size was $1.63 billion in 2023. Factors such as the rising prevalence of chronic diseases and the increased demand for cost-effective and quality healthcare will drive the market growth at a CAGR of more than 4% from 2023 to 2033. Contrast media injectors are devices used to inject contrast media agents into a patient's bloodstream. This process enables the visualization of various pathologies through X-ray, computed tomography, magnetic...
-
Company Insights
NewSamsung Pay – Competitor Profile
Samsung Pay is a mobile payment solution launched by Samsung in August 2015. Samsung Pay is available for a range of Samsung products, including its Galaxy devices and Gear wearable technology. It was the first mobile payment offering to support NFC, magnetic secure transmission, and barcode scanning in a single solution. It is supported by more than 2,800 international and regional banks and credit unions in the US, including Bank of America, Wells Fargo, Citibank, Capital One, PNC, and TD...
-
Product Insights
NewBrainsway Ltd Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our Brainsway Ltd Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. Brainsway Ltd (Brainsway) is a medical device company that develops and markets transcranial magnetic stimulation systems and noninvasive medical device for treatment of neurological and psychiatric disorders. The company provides deep transcranial magnetic stimulation products. It offers deep TMS that used for treatment of depressive episodes in adult patients suffering from depressive disorder. Brainsway conducts various clinical research programs. The...
-
Product Insights
NewCanon Medical Systems Corp Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our Canon Medical Systems Corp Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. Canon Medical Systems Corp (Canon Medical Systems) is a provider of medical diagnostic systems. The company’s major products include computed tomography systems, magnetic resonance imaging systems, ultrasound systems, X-ray; magnetic resonance systems; advanced visualization and nuclear medicine systems. Canon Medical Systems distributes products through subsidiaries and a network of distributors across the world. The company develops medical imaging...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Golimumab in Castration-Resistant Prostate Cancer (CRPC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Golimumab in Castration-Resistant Prostate Cancer (CRPC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Golimumab in Castration-Resistant Prostate Cancer (CRPC) Drug Details: Golimumab...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Golimumab in Type 1 Diabetes (Juvenile Diabetes)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Golimumab in Type 1 Diabetes (Juvenile Diabetes) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Golimumab in Type 1 Diabetes (Juvenile Diabetes) Drug...
-
Company Insights
NewBlock – Competitor Profile
Block (formerly Square) is a US-based payment services provider that was launched in 2009. Effective from December 10, 2021, Square changed its legal name to Block. However, the company continues to offer its merchant services under the Square brand name, enabling businesses to accept payments through methods including debit and credit cards issued by all major scheme providers, as well as NFC-based solutions such as Google Pay and Apple Pay. For offline payments, the company offers an array of traditional...
-
Company Insights
NewCorticoMetrics LLC Pipeline Insight and Competitive Landscape, 2024
Empower your strategies with our CorticoMetrics LLC Pipeline Insight and Competitive Landscape, 2024 report and make more profitable business decisions. CorticoMetrics LLC (CorticoMetrics) is improving the state of clinical decision making in neuroradiology, augmenting qualitative assessment with quantitative analysis of magnetic resonance imaging (MRI) scans of the brain. CorticoMetrics is headquartered in Boston, Massachusetts, the US. GlobalData's Medical Devices company profile report, “CorticoMetrics LLC Pipeline Insight and Competitive Landscape, 2024" provides information about the company overview and analysis on their...
-
Company Insights
NewInlighta Biosciences LLC Pipeline Insight and Competitive Landscape, 2024
Empower your strategies with our Inlighta Biosciences LLC Pipeline Insight and Competitive Landscape, 2024 report and make more profitable business decisions. Inlighta Biosciences LLC specializes in the development of protein-based magnetic resonance imaging (MRI) contrast agents. The company is involved in the creation of novel protein contrast agents, known as ProCA, which are designed to enhance in vivo contrast capabilities. It provides products that includes both non-targeted contrast agents for soft tissues and biomarker targeted molecular imaging contrast agents. The...